Reports received by FDA, by month

July 2012: adverse event reports received by FDA

59,659 drug reports (FAERS) and 39,729 device reports (MAUDE).

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

59,659
drug reports received: 42,700 a year earlier; 53,359
monthly average, preceding 12 months: 11.8% against the average; 39,729
device reports received: 39,088 a year earlier

FDA received 59,659 drug adverse event reports in July 2012, against 42,700 in the same month a year earlier and a monthly average of 53,359 over the preceding 12 months. The MAUDE device database received 39,729 reports that month (39,088 a year earlier).

The drugs listed most often as suspect products were Seroquel (4,066), Enbrel (2,498) and Tysabri (1,465), and the reactions recorded most often were drug ineffective (2,926), death (2,824) and nausea (2,336).

Relative to their own average over the preceding 12 months, the drugs whose report count rose most were Latisse (21.7× its average), Telavic (15.3× its average) and Lumigan (15× its average). A jump in one month usually reflects a batch of reports from a manufacturer, a publicised event or a new product, not a change in what happens to patients.

Drug reports by month, three years to July 2012

Drugs listed most often as suspect products

Drug	Reports	Share of the month
Seroquel	4,066	6.8%
Enbrel	2,498	4.2%
Tysabri	1,465	2.5%
Remicade	1,265	2.1%
Aleve	1,207	2%
Avonex	1,039	1.7%
Nexium	1,032	1.7%
Lyrica	928	1.6%
Gilenya	875	1.5%
Mirena	873	1.5%
Humira	823	1.4%
Pradaxa	755	1.3%
Lipitor	725	1.2%
Coumadin	682	1.1%
Avandia	622	1%

FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Largest rises against their own average

Drug	Reports this month	Times its 12-month average
Latisse	473	21.7×
Telavic	377	15.3×
Lumigan	215	15×
Opcon-A	124	10.3×
Mircera	147	6.5×
Rebetol	240	6.3×
Seroquel	4,066	6.1×
CellCept	151	5.5×

Drugs with at least 50 reports in the month and an average of at least 10 a month over the preceding year. A rise usually reflects a batch of manufacturer reports, a publicised event or a new product.

Reactions recorded most often

MedDRA term	Reports	Share of the month
Drug ineffectivethe medicine did not work as expected	2,926	4.9%
Deaththe patient died; cause not stated by this term	2,824	4.7%
Nauseafeeling sick	2,336	3.9%
Drug dose omissiona dose was missed	2,294	3.8%
Painpain, site not specified	2,116	3.5%
Fatiguetiredness	2,100	3.5%
Malaisegeneral feeling of being unwell	2,089	3.5%
Dyspnoeashortness of breath	2,062	3.5%
Headachehead pain	2,050	3.4%
Insomniadifficulty sleeping	1,782	3%
Dizzinesslight-headedness or unsteadiness	1,710	2.9%
Vomitingbeing sick	1,682	2.8%
Diarrhoealoose or frequent stools	1,585	2.7%
Off label useused for a purpose or in a way not on the label	1,571	2.6%
Falla fall	1,557	2.6%

Devices named most often

Brand	Reports	Share of device reports
Onetouchping Glucosemgmtsystem	1,051	2.6%
Homechoice	706	1.8%
Endotak Reliance	580	1.5%
Ot Ultralink Meter	579	1.5%
Ot Ping Meter	569	1.4%
Paradigm Real-Time Insulin Infusion Pump	553	1.4%
Architect Ca 19-9xr	523	1.3%
Riata Active Fixation	491	1.2%
Homechoice Pro	475	1.2%
Tension Free Vaginal Tape	442	1.1%

Questions about July 2012

How many adverse event reports did FDA receive in July 2012?

59,659 drug reports are in the openFDA FAERS release of 28 Sep 2026, and 39,729 device reports in the MAUDE release of 28 Sep 2026. The same month a year earlier has 42,700 drug reports.

Which drugs were listed most often?

Seroquel (4,066), Enbrel (2,498), Tysabri (1,465), Remicade (1,265) and Aleve (1,207).

Which reactions were recorded most often?

drug ineffective (2,926), death (2,824), nausea (2,336), drug dose omission (2,294) and pain (2,116).

Can the count for a month still change?

Yes. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Older months change little.

Does a busy month mean something happened that month?

Not by itself. The date is when FDA received the report, not when the event occurred, and volume follows manufacturer batches, product launches and publicity. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.